Xin Hong

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5

Novel mutations target distinct subgroups of medulloblastoma

Giles Robinson, Matthew Parker, Tanya A. Kranenburg et al. · Nature · 2012 · 845 citations · Full text

Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity

Timothy Harris, Joseph F. Grosso, Hung‐Rong Yen et al. · The Journal of Immunology · 2007 · 580 citations

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

Michael Hedvat, Dennis Huszar, Andreas Herrmann et al. · Cancer Cell · 2009 · 526 citations · Full text

Tumor Biology, Signaling Pathway, Solid Tumors +8

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

Xin Hong, Chunyan Zhang, Andreas Herrmann et al. · Cancer Research · 2009 · 490 citations · Full text